MILAN (ITALPRESS) – A marketing authorization for Sanofi’s trivalent formulation of the high-dose influenza vaccine, under the trade name Efluelda, has been published in the Official Gazette, and will be available in Italy starting with the upcoming 2025/2026 flu season.The switch from quadrivalent to trivalent flu vaccine responds to WHO guidance, later also endorsed by Ema’s Committee for Medicinal Products for Human Use, which called for the elimination of the B/Yamagata strain from the composition of flu vaccines: the recommendation is based on data from surveillance systems around the world that showed an absence of cases attributable to this virus since March 2020. The high-dose influenza vaccine was developed specifically for influenza protection of adults 60 years of age and older. First introduced in the United States in 2009, it is now available in more than 20 countries. Its trivalent and quadrivalent formulations have helped protect 284 million people globally from influenza. In addition, the high-dose vaccine is the only flu vaccine whose clinical efficacy has been shown to be superior to the standard-dose vaccine in a randomized, controlled trial, which is recognized by the scientific community as the gold standard of evidence.For Mario Merlo, general manager Sanofi Vaccini Italia, “Fostering increased vaccine coverage, especially in a fragile population such as the elderly, is still a public health challenge. As Sanofi we are proud to be able to do our part: as of now we are at the disposal of public health and the regions to optimally plan the next flu campaign. The authorization of the updated formulation of our high-dose vaccine represents an important first step in protecting the elderly from the serious complications of influenza and improving their quality of life.”(ITALPRESS).-Photo: Ipa Agency-
